Stock Benefit Plans and Equity Transactions (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Total Stock Based Compensation

Stock-Based Compensation

Total stock-based compensation for the three and six months ended June 30, 2020 and 2019 is as follows (in thousands):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Cost of revenues	$	128	$	28	$	235	$	56
Research and development		396		174		687		317
Sales, general and administrative		4,051		2,149		7,221		3,590
Total	$	4,575	$	2,351	$	8,143	$	3,963

Summary of Common Stock Reserved for Future Issuance

As of June 30, 2020, the Company had reserved shares of its common stock for future issuance as follows (in thousands):

Stock options outstanding	4,167
Unvested restricted stock award	8,345
Employee stock purchase plan	394
Series A convertible preferred stock	67
Warrants outstanding	25,401
Authorized for future grant under the Distributor and    Development Services plans	6,949
Authorized for future grant under the Management    Objective Strategic Incentive Plan	370
Authorized for future grant under the Company equity    plans	5,487
Total	51,180

Summary of All Outstanding Warrants for Common Stock

A summary of all outstanding warrants for common stock is as follows:

	Number of Warrants		Strike Price		Expiration
2017 PIPE Warrants*		3,255,554	$	2.02	June 2022
2018 PIPE Warrants		11,663,147	$	3.50	May 2023
SafeOp Surgical Merger Warrants		2,199,682	$	3.50	May 2023
2018 Squadron Capital Warrants		845,000	$	3.15	May 2027
2019 Squadron Capital Warrants		4,838,710	$	2.17	May 2027
2020 Squadron Capital Warrants		1,075,820	$	4.88	May 2027
Executive Warrants		1,327,434	$	5.00	December 2022
Other*		195,312	$	3.85	Various through May 2023
Total		25,400,659

* Represents weighted average exercise price.